The invention relates to a method for activating and expanding NKT-like cells in vitro. The method according to the present invention utilizes nucleated somatic cells derived from allogeneic or heterologous subjects to activate and proliferate NKT-like cells of a subject in vitro, and can increase the overall number of the NKT-like cells, the expression of activation markers and the number of killing effector molecules.

The present invention relates to a method for producing a fibrosis-encapsulated tumoroid (FET), and the use of the fibrosis-encapsulated tumoroid. According to the present invention, an analogue that is close to real solid cancer tissue is produced using induced pluripotent stem cell-derived cell. The analogue has significant improvement over conventional tumoroids, which fail to perfectly reflect the characteristics of human solid cancer and have a very high probability of failure in the clinical validation stage. Thus, the present invention is expected to be widely used in the fields of new anticancer drug development and precision medicine.

A method for the ex vivo cultivation of oral mucosal epithelial progenitor cells and oral mucosal epithelial cells includes: subjecting an oral mucosal tissue to an enzymatic digestion treatment with collagenase, so as to obtain cell aggregates which include oral mucosal epithelial progenitor cells and oral mucosal epithelial cells; cultivating the cell aggregates with an amniotic membrane in a serum-free platelet lysate-containing medium in the absence of feeder cells, so that the cell aggregates are adhered onto the amniotic membrane; and subsequently cultivating the cell aggregates adhered on the amniotic membrane in a serum-free proliferation-facilitating medium in the absence of feeder cells.

The present disclosure provides a process for obtaining an expanded primed mesenchymal stem cell population. In the process, the MSCs are cultured in the culture medium comprising a corneal stromal stem cell derived-conditioned medium to obtain the expanded population of the primed mesenchymal stem cell population along with the mesenchymal stem cell derived-conditioned medium. Also, provided is a method of culturing the MSCs in 3D culture using a spheroid-based method or a microcarrier-based method, in order to obtain the expanded primed mesenchymal stem cell population. Further, an exosome preparation obtained from the expanded primed mesenchymal stem cell derived-conditioned medium is also disclosed herein. The present disclosure also discloses a composition comprising an expanded population of the primed mesenchymal stem cells, or a primed mesenchymal stem cell derived-conditioned medium, or an exosome preparation, or combinations thereof.

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.

The present disclosure discloses methods for culturing stem cells in three-dimensional methods. Said method is either a spheroid-based method or a microcarrier-based method. The process as described herein leads to the expansion of the stem cells to obtain an expanded population of the stem cells, and a stem cell derived-conditioned medium. The present disclosure also discloses an expanded population of the stem cells, and a stem cell derived-conditioned medium obtained from the process as described herein. Further, an exosome preparation obtained from the stem cell derived-conditioned medium is also disclosed herein. The present disclosure also discloses a composition comprising an expanded population of the stem cells, or a stem cell derived-conditioned medium, or an exosome preparation, or combinations thereof. Methods of treatment using the composition as described herein is also disclosed in the present disclosure.

The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment.

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.